MARKET

FBLG

FBLG

Fibrobiologics
NASDAQ
1.730
-0.030
-1.70%
Closed 19:30 09/10 EDT
OPEN
1.730
PREV CLOSE
1.760
HIGH
1.796
LOW
1.671
VOLUME
83.79K
TURNOVER
0
52 WEEK HIGH
12.40
52 WEEK LOW
0.6201
MARKET CAP
11.52M
P/E (TTM)
-0.3013
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at FBLG last week (0831-0904)?
Weekly Report · 3d ago
FibroBiologics Secures U.S. Patent For Fibroblast-Based Wound Healing Therapy; Stock Down
NASDAQ · 09/03 15:09
FibroBiologics announces USPTO issued patent on use of fibroblasts
TipRanks · 09/03 12:41
FibroBiologics Secures US Patent For Therapeutic Use Of Fibroblasts For Use In Wound Healing
Benzinga · 09/03 12:37
FibroBiologics Receives Patent From United States Patent And Trademark Office Titled 'Treatment Of Disc Degenerative Disease And Stimulation Of Proteoglycan Synthesis By Fibroblast Conditioned Media And Formulations Thereof'
Benzinga · 09/01 12:43
FibroBiologics announces USPTO issued patent for Fibroblast Conditioned Media
TipRanks · 09/01 12:40
Weekly Report: what happened at FBLG last week (0824-0828)?
Weekly Report · 08/31 09:43
FibroBiologics Releases Third cGMP CYWC628 Drug Product Batch For Shipment To Australia, Supporting Ongoing Phase 1/2 Diabetic Foot Ulcer Trial
Benzinga · 08/27 12:34
More
About FBLG
FibroBiologics, Inc. is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 270+ United States and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. Its advanced product candidates are CYWC628, CYPS317, CYMS101 and CybroCell. It has completed its IND-enabling pre-clinical studies for the development of CYWC628 as a topically administered allogeneic fibroblast cell-based therapy for wound healing. CYPS317 is its allogeneic intravenously administered fibroblast spheroid cell-based investigational therapeutic for the treatment of psoriasis. It is developing CYMS101 as an intravenously administered allogeneic fibroblast single cell, and fibroblast spheroid, cell-based therapy to treat multiple sclerosis (MS).

Webull offers Fibrobiologics Inc stock information, including NASDAQ: FBLG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FBLG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FBLG stock methods without spending real money on the virtual paper trading platform.